lassa
viru
lasv
member
arenavirida
famili
caus
viral
hemorrhag
fever
endem
west
africa
mani
infect
occur
per
year
present
fdaapprov
lasvspecif
vaccin
antivir
agent
although
antivir
drug
ribavirin
shown
efficaci
recent
identifi
smallmolecul
inhibitor
arenaviru
entri
exhibit
submicromolar
antivir
activ
vitro
determin
antivir
util
vivo
test
efficaci
compound
lasv
guinea
pig
model
four
group
strain
guinea
pig
administ
mgkg
mgkg
ribavirin
vehicl
intraperiton
ip
rout
infect
lethal
dose
lasv
strain
josiah
continu
daili
day
control
anim
exhibit
sever
diseas
becom
moribund
day
postinfect
anim
exhibit
fewer
sign
diseas
enhanc
surviv
compar
ribavirin
vehicl
group
bodi
temperatur
group
elev
day
return
normal
day
postinfect
major
anim
treatment
mediat
reduct
viremia
rel
vehicletr
control
overal
surviv
rate
guinea
pig
compar
ribavirin
vehicl
group
data
suggest
may
serv
improv
candid
treatment
lassa
fever
lassa
fever
acut
often
fatal
ill
endem
region
west
africa
includ
countri
liberia
guinea
nigeria
sierra
leon
recent
import
case
nonendem
area
increas
concern
import
case
lassa
fever
report
unit
state
europ
canada
lassa
fever
b
c
import
lassa
fever
atkin
et
al
kitch
et
al
mahdi
et
al
estim
case
lassa
fever
occur
year
fisherhoch
mccormick
mccormick
mccormick
et
al
mortal
rate
hospit
patient
buchmeier
et
al
etiolog
agent
lassa
fever
lassa
viru
lasv
member
arenavirida
famili
rna
virus
famili
divid
old
world
virus
eg
lasv
lymphocyt
choriomening
viru
lcmv
new
world
virus
eg
machupo
guanarito
natur
host
lassa
viru
peridomest
multimamm
rat
mastomi
natalensi
transmiss
human
occur
often
contact
infect
rodent
excreta
lassa
fever
pose
particular
threat
health
care
worker
endem
area
nosocomi
infect
occur
nearli
everi
record
outbreak
fisherhoch
et
al
incub
period
lassa
fever
approxim
day
rang
day
bausch
et
al
frame
et
al
mccormick
et
al
merten
et
al
monath
et
al
earli
stage
diseas
character
onset
gener
flulik
symptom
headach
malais
etc
thu
make
specif
earli
diagnosi
lassa
fever
difficult
mani
diseas
present
similar
manner
endem
area
gastrointestin
manifest
common
sore
throat
typic
accompani
inflammatori
exud
pharyng
observ
two
three
patient
buchmeier
et
al
mccormick
et
al
complic
lassa
fever
report
literatur
includ
mucos
bleed
pleural
pericardi
effus
mccormick
et
al
bleed
tendenc
observ
less
one
third
patient
indic
poor
outcom
develop
sever
edema
buchmeier
et
al
enria
et
al
frame
unilater
bilater
deaf
associ
infectionrel
damag
eighth
cranial
nerv
last
complic
approxim
onethird
patient
releas
hospit
recov
lassa
fever
cummin
cummin
et
al
liao
et
al
current
fdalicens
vaccin
therapeut
immunotherapi
develop
specif
prevent
treat
lassa
fever
addit
support
care
primari
treatment
option
administr
intraven
ribavirin
nucleosid
analogu
antivir
drug
shown
efficaci
highrisk
patient
administ
earli
diseas
typic
patient
lassa
fever
endem
area
present
hospit
late
diseas
progress
diminish
likelihood
success
ribavirin
treatment
ribavirin
caus
hemolyt
anemia
often
doselimit
fuster
et
al
extrem
teratogen
anim
model
addit
ribarivin
combin
therapi
associ
acut
hematolog
mitochondri
pulmonari
hepatocellular
bone
marrow
toxic
especi
patient
coinfect
hepat
c
human
immunodefici
viru
banisadr
et
al
drapeau
et
al
fuster
et
al
kumar
et
al
mira
et
al
frequent
complic
sever
enough
forc
dose
reduct
cessat
treatment
thu
viabl
altern
treatment
necessari
fuster
et
al
varieti
approach
taken
develop
vaccin
therapeut
arenaviru
infect
vaccin
candid
includ
live
attenu
reassort
yellow
fever
virusbas
vesicular
stomat
virusbas
platform
bredenbeek
et
al
carrion
et
al
fisherhoch
mccormick
geisbert
et
al
lukashevich
et
al
potenti
therapeut
arenaviru
infect
includ
novel
therapi
small
interf
rna
sirna
particl
antivir
compound
smallmolecul
inhibitor
viru
entri
andor
replic
et
al
recent
demonstr
sirna
particl
abl
inhibit
lasv
replicon
system
vitro
pyrazin
deriv
current
clinic
trial
influenza
viru
shown
efficaci
arenaviru
infect
vitro
vivo
gowen
et
al
novel
broadspectrum
antivir
demonstr
latestag
efficaci
pichind
viru
hamster
model
biosafeti
surrog
lasv
infect
though
mechan
unknown
gowen
holbrook
yet
test
lasv
anoth
strategi
target
viral
entri
cell
process
mediat
virusencod
envelop
glycoprotein
characterist
arenaviru
glycoprotein
consist
class
envelop
protein
typifi
influenza
hemagglutinin
found
also
retrovirus
paramyxovirus
coronavirus
filovirus
colman
lawrenc
eschli
et
al
york
et
al
glycoprotein
precursor
gpc
process
initi
signal
peptidas
produc
unusu
stabl
signal
peptid
subsequ
posttransl
cleavag
host
cell
proteas
yield
glycoprotein
glycoprotein
subunit
agnihothram
et
al
lenz
et
al
serv
role
receptor
bind
contain
structur
motif
consist
fusogen
subunit
class
envelop
protein
facilit
host
cell
entri
via
aciddepend
membran
fusion
borrow
oldston
burn
buchmeier
di
simon
buchmeier
gallah
et
al
wright
et
al
attempt
interfer
lasv
gpc
process
viral
entri
mediat
subunit
repres
viabl
antivir
strategi
two
group
recent
describ
smallmolecul
inhibitor
lasv
entri
larson
et
al
lee
et
al
least
one
compound
appear
target
subunit
envelop
glycoprotein
larson
et
al
studi
assess
vivo
efficaci
guinea
pig
model
lassa
fever
guinea
pig
practic
small
anim
diseas
model
lassa
fever
inbr
strain
guinea
pig
infect
plaqueform
unit
pfu
ml
lasv
develop
sever
diseas
character
interstiti
pneumonia
pulmonari
edema
pleural
effus
necrosi
kidney
spleen
myocard
result
mortal
day
postinfect
rang
jahrl
et
al
result
diseas
cours
differ
significantli
anim
given
differ
dose
lasv
pfu
jahrl
et
al
lasv
titer
detect
tissu
high
titer
lasv
found
blood
lung
spleen
pancrea
lymph
node
adren
gland
kidney
liver
heart
viru
inocul
subcutan
jahrl
et
al
walker
et
al
evalu
util
lethal
lasv
infect
strain
guinea
pig
model
well
compar
perform
novel
therapeut
ribavirin
current
standard
care
formul
solut
wv
compound
dissolv
acidif
addit
final
volum
hcl
subsequ
neutral
addit
final
volum
naoh
final
ratio
respect
hcl
naoh
solut
femal
hartley
guinea
pig
inject
intraperiton
mgml
solut
volum
either
ml
per
kg
bodi
weight
mgkg
ml
per
kg
mgkg
four
anim
per
dose
use
blood
sampl
collect
two
anim
per
dose
time
point
altern
fashion
blood
sampl
obtain
indic
time
point
fig
jugular
cannula
plasma
isol
g
min
c
plasma
separ
tube
contain
lithium
heparin
bd
microtain
franklin
lake
nj
sampl
store
c
ship
dri
ice
absorpt
system
exton
pa
extract
tomtec
quadra
liquid
handl
system
dilut
acetonitril
contain
ngml
ritonavir
intern
standard
sirocco
protein
precipit
plate
water
corpor
result
suspens
mix
air
aspir
filter
collect
plate
vacuum
spun
briefli
low
speed
filtrat
transfer
chromacol
vial
analysi
liquid
chromatographytandem
mass
spectrometri
lcmsm
use
pe
sciex
api
system
chromatographi
perform
keyston
hypersil
bd
c
column
particl
size
mm
mm
flow
rate
mlmin
mobil
phase
contain
mm
nh
oh
ph
formic
acid
use
perkinelm
seri
micro
pump
autosampl
quantit
perform
calibr
curv
gener
spike
blank
guinea
pig
plasma
qualiti
control
sampl
prepar
independ
weigh
prepar
quantit
manner
ensur
accept
precis
accuraci
strain
guinea
pig
cavia
porcellu
week
old
divid
four
group
group
consist
seven
four
male
three
femal
vehicl
control
eight
four
male
four
femal
anim
treatment
group
ribavirin
solubil
wv
also
use
without
drug
vehicl
control
anim
anesthet
inject
ketamineacepromazin
cocktail
administ
vehicl
control
ribavirin
mgkg
mgkg
mgkg
intraperiton
ip
inject
begin
h
lasv
infect
continu
daili
day
follow
one
group
n
receiv
mlkg
vehicl
control
formul
buffer
alon
one
group
n
receiv
mgkg
mlkg
mgml
formul
ribavirin
one
group
n
receiv
mgkg
mlkg
mgml
formul
one
group
n
receiv
mgkg
mlkg
mgml
formul
viral
infect
carri
biosafeti
level
condit
anim
administ
subcutan
sc
singl
dose
pfu
lasv
strain
josiah
total
volum
l
physiolog
salin
anim
observ
twice
daili
assign
morbid
score
morbid
score
assess
assign
symptom
ill
numer
valu
symptom
evalu
includ
piloerect
visibl
weight
loss
dehydr
orbit
exud
dyspnea
paralysi
hypothermia
sum
number
associ
symptom
ad
day
averag
morbid
score
tabul
daili
treatment
group
blood
sampl
taken
day
postinfect
anim
euthan
nonambulatori
andor
moribund
surviv
anim
euthan
termin
blood
sampl
collect
day
studi
day
postinfect
serum
sampl
analyz
viremia
lasvspecif
antibodi
neutral
antibodi
blood
chemistri
valu
necropsi
perform
anim
tissu
analyz
lasvspecif
histopatholog
immunohistochem
analysi
research
conduct
iacuc
approv
protocol
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
serum
sampl
collect
viral
infect
day
postinfect
analyz
lasvspecif
antibodi
product
elisa
prepar
purifi
irradi
lasv
use
antigen
cell
cultur
supernat
contain
lasv
gradient
purifi
unpublish
method
p
jahrl
expos
cobalt
irradi
rad
total
dose
viral
inactiv
confirm
perform
two
round
plaqu
assay
immunofluoresc
assay
well
microtit
plate
coat
mgml
purifi
irradi
lasv
prepar
incub
overnight
c
plate
wash
three
time
phosphatebuff
salin
plu
tween
pbst
block
h
c
lowfat
milk
solut
wash
three
time
l
twofold
serial
dilut
seri
rang
serum
cell
cultur
medium
ad
well
incub
h
c
bound
antibodi
subsequ
detect
guinea
pigspecif
hrpconjug
secondari
antibodi
immunolog
consult
inc
colorimetr
assay
use
sureblu
tmb
kpl
laboratori
substrat
perform
absorb
valu
obtain
use
microtit
plate
reader
experi
use
serum
collect
lasvinfect
anim
perform
biosafeti
condit
serum
sampl
collect
preand
postinfect
assay
viral
titer
via
standard
plaqu
assay
modif
tomori
et
al
briefli
vero
cell
seed
cell
cultur
plate
adsorb
gentl
rotat
c
co
serial
dilut
serum
h
overlay
molecular
grade
agaros
ebm
basal
medium
eagl
earl
salt
fortifi
fetal
bovin
serum
gml
gentamicin
appli
well
allow
solidifi
overlay
solidifi
cell
incub
c
co
day
stain
neutral
red
overnight
incub
c
stain
plaqu
count
record
neutral
capabl
antibodi
serum
analyz
standard
plaquereductionneutr
test
modif
hooper
et
al
briefli
twofold
dilut
serum
l
volum
incub
h
c
lasv
dilut
approxim
pfu
per
serum
dilut
incub
serum
dilutionviru
mixtur
ad
vero
cell
seed
cell
cultur
plate
remaind
procedur
describ
plaqu
assay
plaqu
count
compar
control
well
contain
cell
infect
pfu
lasv
preincub
guinea
pig
serum
neutral
antibodi
titer
yield
reduct
plaqu
determin
serum
sampl
collect
preand
postinfect
dilut
analyz
glucos
blood
urea
nitrogen
creatinin
uric
acid
calcium
albumin
total
protein
alanin
aminotransferas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
ap
total
bilirubin
gamma
glutamyl
transferas
amylas
approxim
l
serum
dilut
appli
gener
chemistri
rotor
evalu
piccolo
pointofcar
blood
chemistri
analyz
abaxi
valu
serum
sampl
normal
dilut
record
compil
tissu
collect
anim
necropsi
store
buffer
formalin
solut
held
biocontain
day
tissu
histopatholog
underw
routin
histolog
process
embed
paraffin
section
stain
hematoxylin
eosin
immunohistochemistri
perform
tissu
section
use
mous
monoclon
antibodi
lasv
dilut
commerci
avail
immunoperoxidas
kit
envis
system
dako
carpinteria
ca
deparaffin
peroxidas
block
tissu
section
incub
primari
antibodi
room
temperatur
h
secondari
antibodi
incub
counterstain
hematoxylin
initi
vivo
test
perform
guinea
pig
found
toler
well
administ
daili
intraperiton
inject
either
mgkgday
day
assess
daili
observ
bodi
weight
termin
necropsi
data
shown
blood
plasma
obtain
first
last
dose
analyz
liquid
chromatographymass
spectrometri
lcm
assess
level
fig
show
pharmacokinet
initi
dose
concentr
similar
final
dose
indic
substanti
accumul
data
shown
plasma
concentr
maintain
well
excess
vitro
effect
concentr
ec
nm
equival
ngml
provid
support
valid
assess
vivo
efficaci
dose
scheme
larson
et
al
thirtyon
strain
guinea
pig
divid
four
treatment
group
lowdos
mgkg
highdos
mgkg
ribavirin
mgkg
vehicl
alon
dose
chosen
exceed
maximum
recommend
volum
daili
ip
inject
buffer
formul
vehicl
use
four
group
one
hour
initi
treatment
dose
anim
expos
subcutan
pfu
lasv
josiah
strain
infect
dose
uniformli
lethal
strain
guinea
pig
repres
greater
ld
jahrl
et
al
surviv
anim
continu
receiv
daili
treatment
day
postinfect
daili
dose
total
vehicletr
anim
succumb
lasv
infect
day
postinfect
ribavirintr
anim
succumb
day
postinfect
fig
one
anim
mgkg
treatment
group
die
much
earlier
day
postinfect
expect
lasvinfect
guinea
pig
bredenbeek
et
al
carrion
et
al
jahrl
jahrl
et
al
anim
develop
infect
wound
right
hind
foot
day
postinfect
becam
ulcer
day
four
although
administ
topic
antibiot
could
rule
injuri
contribut
death
guinea
pig
unlik
anim
studi
anim
never
becam
febril
daili
bodi
weight
monitor
reveal
progress
weight
loss
group
mgkg
group
fig
mgkg
group
lost
bodi
weight
initi
weight
loss
stabil
day
postinfect
guinea
pig
began
gain
weight
start
approxim
day
postinfect
vehicl
ribavirintr
group
lost
bodi
weight
steadi
rate
euthan
moribund
anim
treatment
group
experienc
elev
bodi
temperatur
start
day
postinfect
fig
howev
fever
bodi
temperatur
c
treat
group
resolv
major
anim
day
postinfect
morbid
score
observ
record
daili
anim
fig
score
consist
higher
vehicl
ribavirin
group
group
eventu
becam
virem
postinfect
fig
howev
day
postinfect
half
four
eight
ribavirintr
seven
total
anim
exhibit
detect
serum
titer
pfuml
vehicletr
anim
titer
pfuml
day
postinfect
averag
viremia
treat
guinea
pig
n
pfuml
compar
ribavirin
treat
anim
n
pfuml
anim
receiv
vehicl
control
n
survivor
day
postinfect
treat
anim
began
clear
viremia
day
postinfect
viremia
undetect
major
anim
day
postinfect
lasvspecif
detect
ribavirintr
group
start
day
postinfect
timepoint
fig
lasvspecif
respons
detect
either
control
ribavirintr
group
data
averag
valu
acquir
sampl
time
group
presenc
neutral
antibodi
evalu
avail
sera
treat
control
group
neutral
antibodi
detect
either
control
ribavirintr
group
use
method
describ
evalu
group
show
presenc
neutral
activ
earli
day
given
presenc
circul
treatment
regimen
neutral
activ
could
well
mediat
day
postinfect
howev
interf
residu
expect
remain
termin
elimin
halflif
guinea
pig
approxim
h
day
postinfect
serum
two
treatment
group
show
signific
neutral
abil
titer
demonstr
either
reduct
prnt
reduct
prnt
plaqu
present
tabl
titer
list
reciproc
dilut
result
either
reduct
plaqu
compar
control
nd
detect
blood
chemistri
analyt
test
three
display
statist
signific
differ
treatment
group
vehicl
control
analyt
test
alt
ast
ap
fig
group
also
display
elev
alt
ast
lesser
degre
control
surviv
anim
group
display
elev
level
alt
ast
alp
rel
normal
level
cours
studi
experienc
increas
alt
ast
studi
endpoint
tabl
summar
result
patholog
analysi
time
death
infect
day
postinfect
vehicl
control
group
day
postinfect
ribavirintr
group
anim
surviv
treatment
group
succumb
day
postinfect
histolog
chang
similar
three
group
vari
sever
common
histolog
observ
includ
hepat
necrosi
interstiti
pneumonia
lymphadenopathi
fig
less
consist
note
lesion
includ
endocard
pancard
renal
tubular
degener
periton
anim
within
group
least
sever
chang
anim
ribavirin
group
sever
lesion
vehicl
control
group
anim
acut
cours
diseas
shortest
time
death
gener
moder
occasion
sever
lesion
immunohistochem
reactiv
found
primarili
macrophag
lung
liver
spleen
group
fig
surviv
anim
evalu
gener
found
unremark
evid
interstiti
pneumonia
mild
hepatocellular
degener
necrosi
note
sever
anim
howev
immunohistochemistri
neg
presenc
viru
tissu
examin
surviv
anim
lasv
signific
human
pathogen
new
treatment
option
need
pilot
studi
provid
proof
concept
smallmolecul
inhibitor
arenaviru
entri
protect
anim
lethal
lasv
infect
although
infect
anim
becam
virem
develop
fever
exhibit
clinic
sign
diseas
piloerect
reduc
appetit
weight
loss
treatment
significantli
limit
diseas
prevent
fatal
outcom
major
anim
viremia
particular
measur
serum
titer
dramat
suppress
human
patient
popul
lasv
viremia
correl
directli
clinic
outcom
mccormick
similar
observ
made
monkey
baiz
et
al
jahrl
et
al
guinea
pig
model
jahrl
et
al
although
weight
loss
promin
symptom
lasv
anim
model
typic
manifest
sever
day
postinfect
carrion
et
al
lukashevich
et
al
weight
declin
steadili
throughout
first
two
week
studi
three
four
group
experienc
averag
weight
loss
mgkg
group
exceed
suggest
weight
loss
might
exacerb
daili
inject
volum
test
articl
three
highloss
group
receiv
time
much
volum
mgkg
group
effect
appear
correl
vehicl
wv
ribavirin
animalhandl
protocol
ribavirin
demonstr
antivir
activ
broad
rang
viru
famili
includ
arenavirus
use
posit
control
vivo
antivir
activ
ribavirin
dose
scheme
chosen
conveni
one
within
toler
rang
guinea
pig
kenyon
et
al
yet
one
report
efficaci
arenaviru
infect
lucia
et
al
may
necessarili
optim
dose
regimen
howev
dose
clearli
demonstr
antivir
activ
studi
shown
reduc
viremia
prolong
surviv
although
extend
ribavirin
treatment
beyond
day
use
studi
might
improv
surviv
noteworthi
viremia
higher
ribavirintr
anim
anim
even
dose
period
cursori
report
literatur
respect
ribavirin
efficaci
lasv
guinea
pig
mix
describ
protect
jahrl
peter
peter
et
al
stephen
et
al
also
report
ipadminist
ribavirin
extend
timetodeath
lasvexpos
guinea
pig
littl
effect
surviv
rate
huggin
consist
observ
report
likewis
ribavirin
administ
sc
mgkgday
shown
prolong
death
virusexpos
hartley
guinea
pig
without
enhanc
surviv
kenyon
et
al
ribavirintr
anim
studi
though
experienc
enhanc
surviv
compar
vehicl
control
group
exhibit
higher
morbid
score
fig
treatment
group
nonhuman
primat
model
howev
ribavirin
shown
clear
efficaci
lasv
jahrl
et
al
though
complet
protect
surviv
anim
symptom
ill
includ
fever
weight
loss
dramat
reduct
serum
viral
titer
observ
surviv
anim
peak
viremia
may
suffici
protect
develop
product
immun
respons
serum
surviv
anim
collect
time
point
postinfect
abil
neutral
lasv
vitro
prnt
test
though
ribavirintr
anim
experienc
prolong
surviv
compar
vehicl
control
group
none
anim
develop
neutral
antibodi
titer
time
point
despit
fact
group
robust
antilasv
respons
measur
elisa
fig
interestingli
one
anim
mgkg
treatment
group
succumb
day
postinfect
yet
minimum
viral
titer
pfuml
termin
serum
immunohistochemistri
fail
identifi
viru
tissu
sampl
examin
histolog
analysi
reveal
interstiti
pneumonia
lymph
node
hyperplasia
splenic
deplet
degre
similar
observ
surviv
anim
howev
anim
exhibit
signific
viremia
pfuml
day
postinfect
sampl
termin
serum
anim
neutral
titer
similar
surviv
anim
repres
exampl
liver
row
lung
row
heart
row
shown
necrosi
liver
arrow
sever
vehicl
control
ribavirin
group
mgkg
mgkg
survivor
group
hepat
necrosi
present
much
lesser
degre
lung
interstiti
pneumonia
thicken
alveolar
wall
congest
alveolar
edema
inflamm
present
group
ribavirin
group
sever
within
heart
inflamm
endocard
present
arrow
ribavirin
mgkg
group
neutral
abil
serum
sampl
surviv
anim
unexpect
result
previou
report
shown
neutral
antibodi
appear
later
day
postinfect
surviv
lasvinfect
guinea
pig
jahrl
et
al
appear
play
signific
recoveri
role
human
case
although
formal
possibl
exist
residu
compound
present
serum
mediat
neutral
lasv
explan
seem
unlik
day
day
sampl
drawn
day
last
compound
dose
deliv
thu
result
suggest
specif
immun
respons
lasv
produc
survivor
one
possibl
treatment
may
mitig
lasvassoci
lymphopenia
jahrl
et
al
thu
allow
time
humor
immun
respons
lack
strong
product
lasvspecif
treat
anim
measur
elisa
may
due
sever
factor
anim
becam
virem
vari
degre
studi
possibl
lasvspecif
antibodi
present
serum
bound
free
antigen
thu
prevent
bind
immobil
antigen
elisa
addit
unknown
effect
irradi
antigen
epitop
lasv
thu
low
specif
antibodi
titer
observ
may
also
due
weaken
lasv
antigen
dose
mgkgday
suffici
provid
level
protect
lethal
lasv
infect
differ
two
treatment
group
remark
although
neither
fulli
protect
possibl
lower
dose
suffici
yield
maximum
antivir
effect
perhap
group
size
small
detect
differ
surviv
rate
two
dose
anoth
consider
within
context
experi
lower
dose
provid
less
anim
higher
dose
expos
anim
higher
volum
vehicl
weight
loss
associ
vehicl
volum
may
exacerb
diseas
offset
addit
quantiti
antivir
compound
effect
might
contribut
poor
surviv
rate
ribavirintr
group
well
group
receiv
vehicl
volum
mgkg
unexpectedli
surviv
anim
treatment
group
experienc
elev
liver
enzym
ast
alt
studi
endpoint
level
ast
alt
elev
surviv
anim
return
normal
rang
day
postinfect
becom
elev
studi
endpoint
one
five
surviv
anim
mgkg
treatment
group
three
five
mgkg
treatment
group
experienc
late
increas
alt
level
surviv
anim
experienc
late
increas
ast
level
vari
degre
late
increas
liver
enzym
occur
despit
survivor
clinic
sign
ill
littl
detect
viremia
studi
endpoint
repeat
analys
possibl
due
limit
sampl
volum
histolog
surviv
anim
elev
liver
enzym
also
evid
mild
hepatocellular
degener
andor
necrosi
necropsi
laboratori
report
multifoc
hepat
necrosi
hartley
guinea
pig
unrel
age
overal
health
maeda
et
al
maeda
et
al
observ
guinea
pig
old
anim
display
multipl
necrot
lesion
commonli
coagul
necrosi
absenc
known
diseas
maeda
et
al
inde
observ
phenomenon
laboratori
well
uninfect
strain
guinea
pig
earli
stage
lasv
infect
observ
liver
patholog
correspond
elev
enzym
level
anoth
potenti
explan
elev
liver
enzym
could
hemolysi
sampl
well
known
caus
overestim
ast
alt
sonntag
fact
anoth
symptom
hemolysi
depress
alkalin
phosphatas
lippi
et
al
sonntag
seen
parallel
sampl
elev
ast
alt
alkalin
phosphatas
level
report
actual
increas
lasvinfect
guinea
pig
lukashevich
et
al
suggest
depress
level
seen
may
consist
hemolysi
liver
damag
final
subsequ
lasv
infect
studi
strain
guinea
pig
exhibit
phenomenon
r
carrion
person
commun
sa
followup
studi
survivor
display
normal
liver
enzym
valu
ultim
find
may
incident
unrel
either
lasv
infect
treatment
addit
studi
help
resolv
work
demonstr
effect
limit
viral
replic
anim
model
lassa
fever
protect
major
anim
lethal
diseas
futur
studi
examin
differ
dose
regimen
eg
amount
frequenc
durat
drug
combin
postinfect
treatment
acquisit
protect
immun
among
treat
survivor
given
potenc
abil
inhibit
hemorrhag
arenavirus
vitro
larson
et
al
vivo
valid
bolster
prospect
candid
develop
